MedPath

A Proof-of-Concept Study Investigating the Safety and Efficacy of ZT-031 on Hip Fracture Healing in Men and Postmenopausal Women

Phase 2
Withdrawn
Conditions
Hip Fracture
Interventions
Other: placebo
Registration Number
NCT00787358
Lead Sponsor
Zelos Therapeutics
Brief Summary

The purpose of this research study is to test if an experimental drug called ZT-031 can help men over 30 years or post-menopausal women over 55 years of age with certain types of hip fracture to heal better or faster following surgery and to determine if ZT-031 is safe for patients with fractures. To be allowed in the study you have to have a type of hip fracture that requires surgery that is being studied (intertrochanteric fracture). You must also otherwise be in good health, with no serious diseases such as cancer, neurologic disease, other bone disease, liver, heart or kidney disease. You must be able to inject yourself every day with the study medication using an injection pen, like that used for insulin injections.

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Placeboplacebo-
ZT-031ZT-031-
Primary Outcome Measures
NameTimeMethod
Compression hip screw (CHS) migration: the difference in the tip apex distance (TAD) post-operatively to that at Visit 7/Week 1616 weeks
Secondary Outcome Measures
NameTimeMethod
Screw barrel impaction distance16 weeks
Screw cut-out and/or other hardware failure16 weeks
Incidence of fracture non-union16 weeks
Need for surgical revision with or without hardware removal16 weeks

Trial Locations

Locations (1)

J. Edward Puzas

🇺🇸

Rochester, New York, United States

© Copyright 2025. All Rights Reserved by MedPath